Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 3:14 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 73–96 of 239 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Buffered Saline Clear all

Conditions: Salmonella
Interventions: CVD 1902, a Salmonella enterica Serovar Paratyphi A live, oral vaccine, Placebo; Biological · Other
Lead sponsor: University of Maryland, Baltimore; Other
Eligibility: 18 Years to 45 Years
Enrollment: 51 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2013
U.S. locations: 2
States / cities: Baltimore, Maryland

Conditions: Gonococcal Infection
Interventions: Cefixime, Ceftriaxone, Ciprofloxacin, Neisseria gonorrhoeae strain FA1090 A26, Neisseria gonorrhoeae strain FA7537; Drug · Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 36 Years · Male only
Enrollment: 27 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Healthy
Interventions: Rivipansel; Drug
Lead sponsor: GlycoMimetics Incorporated; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 48 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Breast Cancer
Interventions: TMEM-MRI, FNA; Device · Procedure
Lead sponsor: Montefiore Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 95 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2026
U.S. locations: 1
States / cities: The Bronx, New York

Conditions: Avian Influenza, Influenza, Influenza Immunisation
Interventions: AS03, Inactivated influenza H7N9 vaccine, Influenza Virus Quadrivalent Inactivated Vaccine, Phosphate Buffered Saline (PBS) diluent; Drug · Biological · Other
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 19 Years to 64 Years
Enrollment: 149 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2019
U.S. locations: 4
States / cities: Birmingham, Alabama • Baltimore, Maryland • Cincinnati, Ohio + 1 more

Conditions: Osteoarthritis, Hip
Interventions: Synvisc-One (hylan G-F 20), Placebo; Device
Lead sponsor: Genzyme, a Sanofi Company; Industry
Eligibility: 35 Years and older
Enrollment: 357 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2015
U.S. locations: 45
States / cities: Burmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 41 more

Conditions: Malaria, Falciparum
Interventions: FMP1/AS02, RTS,S/AS02, AS02 adjuvant alone, Malaria challenge; Biological · Other
Lead sponsor: U.S. Army Medical Research and Development Command; Federal
Eligibility: 18 Years to 45 Years
Enrollment: 72 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Started 2001
U.S. locations: 1
States / cities: Silver Spring, Maryland

Conditions: Mumps
Interventions: CVM150, CVM26, Placebo; Biological · Other
Lead sponsor: CyanVac LLC; Industry
Eligibility: 18 Years to 29 Years
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2027
U.S. locations: 3
States / cities: Rochester, New York • Cincinnati, Ohio • North Charleston, South Carolina

Conditions: Knee Osteoarthritis
Interventions: Hymovis Intra-articular Injection, Phosphate Buffered Saline Injection; Device · Procedure
Lead sponsor: Fidia Farmaceutici s.p.a.; Industry
Eligibility: 40 Years and older
Enrollment: 800 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 32
States / cities: Birmingham, Alabama • Tucson, Arizona • Encinitas, California + 28 more

Conditions: Chronic Spinal Cord Injury
Interventions: AXER-204, Placebo; Drug
Lead sponsor: ReNetX Bio, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 52 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 6
States / cities: Los Angeles, California • Atlanta, Georgia • Chicago, Illinois + 3 more

Conditions: Influenza
Interventions: AS03 Adjuvant, Phosphate Buffered Saline (PBS) diluent, Sanofi H5N1 Antigen; Drug · Other · Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 49 Years
Enrollment: 245 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2012
U.S. locations: 4
States / cities: Baltimore, Maryland • Nashville, Tennessee • Houston, Texas + 1 more

Conditions: Immunologic Tests
Interventions: Serum samples; Other
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 6 Months to 64 Years
Enrollment: 414 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2018
U.S. locations: 1
States / cities: New York, New York

Conditions: NLRC4-MAS, XIAP Deficiency
Interventions: Tadekinig alfa, 0.9% sodium chloride; Drug · Other
Lead sponsor: AB2 Bio Ltd.; Industry
Eligibility: Not listed
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2023
U.S. locations: 6
States / cities: La Jolla, California • Atlanta, Georgia • Boston, Massachusetts + 3 more

Conditions: Gonorrhea Male
Interventions: Cefixime, Ceftriaxone, Ciprofloxacin, Neisseria gonorrhoeae strain FA1090, Meningococcal Group B Vaccine, Influenza Vaccine, Tetanus-diptheria Vaccine; Drug · Biological
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 18 Years to 35 Years · Male only
Enrollment: 65 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2026
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: HIV Infections
Interventions: DNA plasmid vaccine, Recombinant adenoviral serotype 5 (rAD5) vector vaccine, DNA vaccine placebo, HIV-1 recombinant adenovirus vaccine placebo; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 50 Years · Male only
Enrollment: 2,504 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2017
U.S. locations: 22
States / cities: Birmingham, Alabama • Los Angeles, California • San Francisco, California + 15 more

Conditions: COVID-19, Healthy
Interventions: Optate, Placebo; Drug
Lead sponsor: Indiana University; Other
Eligibility: 18 Years to 60 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2027
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: Anterior Uveitis
Interventions: 40 mg/mL Dexamethasone phosphate ophthalmic solution, Prednisolone Acetate (1%) Eyedrops, 100 mM sodium citrate buffer solution, Placebo Eyedrops; Drug
Lead sponsor: Eyegate Pharmaceuticals, Inc.; Industry
Eligibility: 12 Years to 85 Years
Enrollment: 193 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 39
States / cities: Birmingham, Alabama • Chandler, Arizona • Phoenix, Arizona + 34 more

Conditions: Retinitis Pigmentosa
Interventions: CNTO 2476; Drug
Lead sponsor: Centocor, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2013
U.S. locations: 3
States / cities: Miami, Florida • Southwest Portland, Oregon • Dallas, Texas

Conditions: Respiratory Syncytial Virus Infections
Interventions: MVA-BN-RSV, Placebo; Biological · Other
Lead sponsor: Bavarian Nordic; Industry
Eligibility: 55 Years and older
Enrollment: 420 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2018
U.S. locations: 12
States / cities: Redding, California • San Diego, California • The Villages, Florida + 9 more

Conditions: Meningitis, Meningococcemia, Pertussis, Tetanus, Diphtheria
Interventions: T dap + Meningococcal Polysaccharide Diphtheria Toxoid Conj., Tdap + Meningococcal Polysaccharide Diphtheria Toxoid Conj., Meningococcal Polysaccharide Diphtheria Toxoid Conj. + T dap; Biological
Lead sponsor: Sanofi Pasteur, a Sanofi Company; Industry
Eligibility: 11 Years to 17 Years
Enrollment: 1,345 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005 – 2007
U.S. locations: 20
States / cities: Jonesboro, Arkansas • Little Rock, Arkansas • Boulder, Colorado + 17 more

Conditions: Cholera
Interventions: PXVX0200, placebo; Biological
Lead sponsor: Bavarian Nordic; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 197 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2014
U.S. locations: 3
States / cities: Baltimore, Maryland • Cincinnati, Ohio • Burlington, Vermont

Conditions: Chikungunya Virus Infection
Interventions: VLA1553, Placebo; Biological
Lead sponsor: Valneva Austria GmbH; Industry
Eligibility: 18 Years and older
Enrollment: 4,128 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2021
U.S. locations: 44
States / cities: Chandler, Arizona • Phoenix, Arizona • Tempe, Arizona + 39 more

Conditions: Bronchopulmonary Dysplasia
Interventions: UNEX-42, Phosphate-buffered saline; Biological
Lead sponsor: United Therapeutics; Industry
Eligibility: 3 Days to 14 Days
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 6
States / cities: Aurora, Colorado • Boston, Massachusetts • Jackson, Mississippi + 1 more

Conditions: Avian Influenza, Influenza Immunisation
Interventions: A/H7N9, AS03, Phosphate Buffered Saline (PBS) diluent; Biological · Drug · Other
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 19 Years to 70 Years
Enrollment: 304 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2020
U.S. locations: 9
States / cities: Atlanta, Georgia • Iowa City, Iowa • Baltimore, Maryland + 6 more

Search by objective public record fields.

Safety and Immunogenicity of CVD 1902 Oral Attenuated Vaccine to Prevent S. Paratyphi A Infection

Experimental Human Infection With Neisseria Gonorrhoeae

A Study to Evaluate the Effect of IV Doses of GMI-1070 on Qtc Intervals in Healthy African-American Adult Subjects

TMEM-MRI: A Pilot Feasibility Study of MRI for Imaging of TMEM in Patients With Operable Breast Cancer

Co-Administration of AS03 Adjuvanted A/H7N9 IIV With IIV4

A Study of the Safety and Effectiveness of Synvisc-One® (Hylan G-F 20) in Patients With Primary Osteoarthritis of the Hip

Safety and Preliminary Efficacy of the Malaria Vaccine Candidates Falciparum Merozoite Protein-1 (FMP1) and SmithKlineBeecham (SKBB) Candidate Malaria Vaccine RTS,S

A Phase 1 Trial of Intranasal Mumps Virus Vaccines in Healthy Adults

Hymovis™ Versus Placebo in Knee Osteoarthritis

AXER-204 in Participants With Chronic Spinal Cord Injury

H5N1 Mix and Match With AS03

A Laboratory Evaluation of the Humoral Immune Response in Adults and Children to the H1 Hemagglutinin (HA) Stalk Domain and Other Influenza A Virus Protein Epitopes, After Administration of GlaxoSmithKline (GSK) Biologicals' Pandemic Influenza Vaccines

Therapeutic Use of Tadekinig Alfa in NLRC4 Mutation and XIAP Deficiency

Efficacy of Immunization With 4C-MenB in Preventing Experimental Urethral Infection With Neisseria Gonorrhoeae

Safety and Effectiveness of HIV-1 DNA Plasmid Vaccine and HIV-1 Recombinant Adenoviral Vector Vaccine in HIV-Uninfected, Circumcised Men and Male-to-Female (MTF) Transgender Persons Who Have Sex With Men

A Nasal Treatment for COVID-19

Safety and Efficacy Study of Iontophoretic Dexamethasone Phosphate Ophthalmic Solution to Treat Non-Infectious Anterior Segment Uveitis

A Study to Evaluate the Safety of CNTO 2476 in Patients With Advanced Retinitis Pigmentosa

RSV-MVA-BN Vaccine Phase II Trial in ≥ 55 Year Old Adults

Study of Menactra® in US Adolescents When Administered Concomitantly With Tdap Vaccine

Safety and Efficacy Challenge Study of Live Oral Cholera Vaccine Candidate,PXVX0200, to Prevent Cholera

Pivotal Study to Evaluate Safety and Immunogenicity of a Live-Attenuated Chikungunya Virus Vaccine Candidate in Adults

A Safety Study of IV Stem Cell-derived Extracellular Vesicles (UNEX-42) in Preterm Neonates at High Risk for BPD

2017 A/H7N9 IIV Revaccination